1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

B.T. Li, David Planchard, Kōichi Goto, Egbert F. Smit, J. De Langen, Yasushi Goto, Kiichiro Ninomiya, Toshio Kubo, M. Pérol, Enriqueta Felip, H. Hayashi, Kazuhiko Nakagawa, Junichi Shimizu, Misako Nagasaka, Kaline Pereira, Ayumi Taguchi, Ahmed Ali, Maha Karnoub, Rie Yonemochi, Pasi A. Jänne